Tauroursodeoxycholic acid inhibits intestinal inflammation and barrier disruption in mice with non‐alcoholic fatty liver disease
British Journal of Pharmacology2017Vol. 175(3), pp. 469–484
Citations Over TimeTop 10% of 2017 papers
Weijun Wang, Jinfang Zhao, Wenfang Gui, Dan Sun, Haijiang Dai, Li Xiao, Huikuan Chu, Fan Du, Qingjing Zhu, Bernd Schnabl, Kai Huang, Ling Yang, Xiaohua Hou
Abstract
TUDCA attenuates the progression of HFD-induced NAFLD in mice by ameliorating gut inflammation, improving intestinal barrier function, decreasing intestinal fat transport and modulating intestinal microbiota composition.
Related Papers
- → Serum metabolome and targeted bile acid profiling reveals potential novel biomarkers for drug-induced liver injury(2019)50 cited
- → Creatine supplementation protects against diet-induced non-alcoholic fatty liver but exacerbates alcoholic fatty liver(2022)9 cited
- → Bile acids (taurocholic acid, taurodeoxycholic acid, taurochenodeoxycholic acid, tauroursodeoxycholic acid) develop esophageal cancer in a rat model of duodenoesophageal anastomosis after total gastrectomy(2020)4 cited
- → What Is a Giant Panda? A Query About Its Place Among The Ursidae(2004)1 cited
- → Features of the course of alcoholic liver disease at the cirrhosis stage associated with non-alcoholic fatty liver disease(2020)